Study Suggests Surrogate Endpoint May Reflect Longer Benefit of Early HER2 Breast Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb) – Last year at the American Society of Clinical Oncology's annual meeting, some experts questioned whether pathologic complete response as an endpoint was truly reflecting longer-term outcomes for early-stage breast cancer patients treated before surgery with HER2-targeting breast cancer agents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.